Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P‐glycoprotein

Monoclonal antibodies (MAbs) recognizing external epitopes of the human MDRI P‐glycoprotein have been used both for the detection of multidrug‐resistant cells and as specific inhibitors of P‐glycoprotein‐mediated multidrug resistance. Using a panel of recently developed transfected or transgenic cell lines containing variants of the human MDRI and MDR3 P‐glycoproteins, we have compared the specificity and binding properties of the previously isolated MAbs MRK16, HYB‐241, UIC2 and 4E3, and of the newly isolated MAb 7G4. The removal of 1, 2 or all 3 of the N‐glycosylation sites present in the first extracellular loop of MDR1 P‐glycoprotein did not significantly affect the binding of these MAbs. In contrast, a 20 amino acid deletion in the first extracellular loop of MDR1 P‐glycoprotein completely abolished binding of UIC2, whereas the binding of all other MAbs was hardly affected. None of the MAbs tested bound detectably to cell lines containing a high level of the human MDR3 P‐glycoprotein. The differences in the binding specificity between UIC2 and the other tested antibodies parallel the reported functional differences in the ability of these antibodies to inhibit P‐glycoprotein‐mediated drug efflux.

[1]  G. Rudenko,et al.  N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. , 1993, The Journal of biological chemistry.

[2]  T. Tsuruo,et al.  Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody. , 1993, The Journal of biological chemistry.

[3]  F. Baas,et al.  Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. , 1993, Cancer research.

[4]  I. Roninson,et al.  Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Mackensen,et al.  Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. , 1992, Cancer research.

[6]  V. Ling,et al.  P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. , 1991, The New England journal of medicine.

[7]  T. Tsuruo,et al.  Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. , 1991, Journal of the National Cancer Institute.

[8]  T. Tsuruo,et al.  Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Borst,et al.  Multidrug resistance mediated by P-glycoproteins. , 1991, Seminars in cancer biology.

[10]  P. Borst,et al.  Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. , 1991, Cancer research.

[11]  T. Tsuruo,et al.  Expression of the multiple drug resistance gene (mdr‐1) and epitope masking in chronic lymphatic leukaemia , 1990, British journal of haematology.

[12]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[13]  A. M. van der Bliek,et al.  Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. , 1990, Cancer research.

[14]  J. Gariépy,et al.  Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  I. Pastan,et al.  Expression of Multidrug Resistance Gene in Human Cancers , 1989 .

[16]  J. Endicott,et al.  The biochemistry of P-glycoprotein-mediated multidrug resistance. , 1989, Annual review of biochemistry.

[17]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. M. van der Bliek,et al.  Sequence of mdr3 cDNA encoding a human P-glycoprotein. , 1988, Gene.

[19]  J. Bulte,et al.  Monoclonal antibody JSB‐1 detects a highly conserved epitope on the P‐glycoprotein associated with multi‐drug‐resistance , 1988, International journal of cancer.

[20]  D. Housman,et al.  Cloning and characterization of a second member of the mouse mdr gene family , 1988, Molecular and cellular biology.

[21]  I. Pastan,et al.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Childs,et al.  Carbohydrates as antigenic determinants of glycoproteins. , 1987, The Biochemical journal.

[24]  I. Pastan,et al.  A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Tsuruo,et al.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Ling,et al.  Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies , 1985, Nature.

[27]  B. Giovanella,et al.  Exceptional lethality for nude mice of cells derived from a primary human melanoma. , 1985, Cancer research.